JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.625, ISSN: , Volume 3, Issue 1, February 2015
|
|
- Abigail Simmons
- 5 years ago
- Views:
Transcription
1 DETECTION OF BK POLYOMAVIRUS USING REAL TIME PCR AND URINE CYTOLOGY IN 99 RENAL TRANSPLANT RECIPIENTS ASMAA B. AL-OBAIDI 1 KAIS H. ABD 2 MANAL A HABIB 3 HAIDER S. KADHIM 1 HAIDAR A.SHAMRAN 4 1 Microbiology Department, School of Medicine, University of AL-Nahrain, Baghdad, Iraq 2 Center of Kidney Diseases and Transplantation (Ministry of health), Iraq 3 Department of Pathology, School of Medicine, University of Baghdad, Iraq 4 Medical Research Unit, School of Medicine, University of AL-Nahrain, Baghdad, Iraq ABSTRACT BK polyomavirus is one of the common post-transplant viral infections, affecting 15% of renal transplantation recipients (RTR), leading to graft loss in more than half of cases Plasma and urine samples were collected from 99 RTR patient, with 15 Living Donors (LD) and 15 patients with Chronic Kidney Disease (CKD) were taken as controls, BKV load in plasma was detected by real time PCR (RT-PCR), and urine cytology smears were Pap stained for detection of decoy cells (DCs).12.12% (12/99) cases were positive for BKV by RT-PCR, and 27.27% (27/99) RTR patient were decoy positive, among which all of the 12 (RT-PCR) BKV positive patients were decoy positive, and 5 out of these 12 BK viremic patients had biopsy proven BKV nephropathy (BKVN).Our study suggests that BKV should be considered as a cause of nephropathy and allograft loss in RTRs in Iraq. Further research is required for better understanding of this entity. KEYWORDS: Renal Transplant Recipients, BK Polyomavirus and Real Time PCR INTRODUCTION Opportunistic polyomaviruses infections mainly BK virus (BKV) and JC virus has become increasingly common problem in renal transplantation recipients (RTR). Polyomaviruses are circular, double-stranded DNA viruses (1). The most important and commonest among these viruses is BKV infection, which was reported in 15% of renal transplant recipients (RTRs) in the first post-transplant year in the absence an effective prophylaxis strategy (2,3). BKV presents with an asymptomatic gradual rise in serum creatinine with a tubulointerstitial nephritis mimicking rejection, making a treatment dilemma. The decrease in immunosuppression that is needed to treat BKV infection is opposite to the increases in immunosuppressive drugs that are needed to treat rejection (4). 30 years ago, Gardner et al. 131
2 (5) warned: The detection of polyomavirus infection is important, as increased immunosuppression needs to be avoided, to prevent possible complications. After primary infection, BKV establishes its latency in the urinary epithelium and renal tubular epithelial cells. When starting immunosuppression, the virus is reactivated and begins to replicate, causing BK viremia and eventually invade the renal allograft, leading to BK virus nephropathy (BKVN), the rates of BKVN varies, ranging from 1 to 10% (2,3,6,7). BKV detection by quantitative real-time PCR (qrt-pcr) in plasma is very sensitive and specific for predicting the development of BKVN. The focal nature of BKVN, and the makeup of cellular infiltration in a renal allograft with BKVN that is very similar to those with acute rejection, these major limitations for diagnosis by biopsy (8,9), make plasma BKV qrt-pcr the preferred screening method at the majority of transplant centers (6,10,11) In addition, urine cytology screening for viral inclusion-bearing, so called decoy cells (DC) allows for the early identification of BKV infection, and it has a relatively high sensitivity and a negative predictive value above 95%, besides being a cost-effective noninvasive assay (12-14). Detection of decoy cells (DCs) in the urine is one of the earliest assays, in this assay urine was Papanicolaou-stained and examined under light microscope to look for virus infected cells "decoy cells", which are epithelial cells with enlarged nuclei, and large basophilic ground-glass intra-nuclear viral inclusions (12-16). In this study we aimed to investigate the prevalence of BKV in Iraqi RTRs using quantitative real time PCR (qrt-pcr) and decoy cell screening. Subjects and Methods Subjects: This cross-sectional study was conducted from2013 to A total of 99 RTR patients who attend the (Center of Kidney Diseases and Transplantation) in the Medical City of Baghdad, were enrolled in the study. A consent letter was signed by each patient, and the study was approved by the ethical committee of Al-Nahrain University. Urine and plasma samples were collected from the patients, 33 of them had normal renal function, and the remaining 66 had impaired renal function, 78 were males. Two control groups were included in the study, 15 Living Donors (LD) and 15 non-transplanted patients with Chronic Kidney Disease (CKD). Urine cytology: Urine (10-ml aliquots) was centrifuged in Falcon tubes at 1500 rpm for 5 min for decoy cell screening. The supernatant was discarded and the sediment was resuspended in the remaining urine. For each patient; two slides were prepared; one was 132
3 immediately stained with the Papanicolaou method and examined under light microscope at 40 and 100 X; the other was stored unstained at 20 C for confirmation of diagnosis if required. Activation and replication of polyomaviruses was detected by identification of decoy cells (DCs), which are viral inclusion-bearing epithelial cells characterized by a ground-glass appearance with an enlarged nucleus, occupied by a basophilic inclusion surrounded by chromatin (14,15). Some of the DCs appear resembling the tail of a comet (17). For decoy cells quantification; a cut-off level of 10 decoy cells / ThinPrep slide, is defined as decoy positive (11). In addition to the quantification of common ground-glass decoy cells, the uncommon (clumped) variants were also looked for; as their presence reflects the pathological stages of BKVN, if the uncommon (clumped) variants are more than 25% of the total decoy cell count; then BKVN can be predicted with more than 75% probability (18) DNA Extraction: Viral DNA was extracted from 200μl of plasma using a Bosphore Viral DNA Extraction Spin Kit according to the manufacturer s protocol which is based on silica membrane column separation method (Anatolia Geneworks, Turkey), and then was eluted from the column with 40μl elution buffer. Real time PCR: Quantification of BKV plasma viral load was done Using Bosphore BKV Quantification Kit, which detects and quantitates the four main genotypes of BK Virus DNA in human plasma. A region within the BKV large T-antigene (LT) encoding gene was amplified. Fluorescence detection is accomplished using the FAM filter, and to check PCR inhibition an internal control is incorporated into the system. The internal control was detected with the Cy5 filter. Quantitation of BK viral load was performed using four quantitated BKV DNA controls, ranging from 1x10 4 copies/ml to 1x10 7 copies/ml. Statistical analysis was performed with the software SPSS version 21.0, and Microsoft Excel Categorical data formulated as count and percentage. Fisher exact test was used to describe the association of these data, in addition to relative risk study (RR). Numerical data were described as mean, standard deviation of mean. Independent sample t- test used for comparison between two groups while analysis of variance (ANOVA) was used for comparison among more than two groups. p 0.05 was considered statistically significant. 133
4 Results Out of these 99 RTR, 78 (78.79%) were males. The mean age was 37.01±1.31 ranging between 18 and 67 years, and the mean ages of the two control groups were (38.5±2.8) and (38.4±2.7) years for LD and CKD, respectively. The mean posttransplantation period in the RTR was 17.53±0.97 months ranging from 2-30 months, and their mean serum creatinine value was 2.33±1.7.Among these 99 RTRs, 19.19% had renal allograft rejection, five of them (5.05%) were receiving antithymocyte globulin (ATG) as anti-rejection therapy, 5.05% had biopsy proven BK virus nephropathy (BKVN), 4.04% had ureteric stenosis, and 43.44% had donor+/recipient+ CMV serostate Papanicolaou-stained urine cytology smears revealed 27 out of 99 RTR (27.27%) had positive decoy cells (DC) shedding, as compared with both control groups; LD and CKD who were all DC negative, p=0.001, in addition, uncommon DCs variants were present in 8 out of 99 RTR (8.08%).The most frequent variant of DCs was the amorphous, basophilic, groundglass like nuclear appearance. While in the other variants (uncommon type), the nucleus appeared eosinophilic and granular, and could be surrounded by a halo, or with a finely granular without a halo, figure (1). In addition, the results of this study revealed that 19 out of these 27 cases (70.4%) were males, their mean age was 34±7 years with no significant correlation with decoy cell positivity, and their mean post-transplant period was 18.2±8 months which also not significantly correlated with decoy cell positivity. On the other hand, 21/27 (77.8%) of these DC positive patients had impaired renal function with a mean serum creatinine value 2.3±0.9 mg/dl, which is significantly correlated with DC positivity (p=0.01), and all of the 5 patients who had biopsy-proven BKVN had positive urine cytology for DCs, i.e. 18.5% of them. Two main standard immunosuppressive regimes are mainly followed in our transplantation center in Baghdad; the old regimen which includes cyclosporine A (CSA), mycophenolate (MMF), and prednisolone, the second regimen includes tacrolimus (TAC) instead of CSA, in addition to MMF and prednisolone. On comparing with the type of immunosuppression used, 55.6% of DC positive patients were on tacrolimus regimen, and 44.4% were on cyclosporine A regimen, which is not significantly correlated with DC positivity, while 4/5 (80%) of patients who were on ATG (anti-thymocyte globulin) were decoy positive, among the 26.3% (5/19) patients who had rejection. Finally, 3/4 (75%) of ureteric stenosis patients were DC positive. 134
5 A B C D Figure (1): Urine cytology: The activation and replication of polyomaviruses can be monitored by searching for viral inclusion-bearing epithelial cells, i.e., decoy cells (DC), in routine urine cytology specimens, (A,B) typical DC phenotype resembling the tail of a comet. And (C) uncommon (atypical) eosinophilic DC, (D) uncommon finely granular DC. Papanicolaou stain, (A&B) X400, (C&D) X1000. BK viremia was detected in (12.12%) 12 out of 99 RTR with a viral load (VL) ranging from 1x10 2 to 1x10 9 copies/ml, and none of the control groups (LD and CKD) was BKV positive. Among the 12 BK positive cases, 7 patients were above 40 years old and 6 of these 7 patients had BK VL more than 10 3 copies/ml, 10 out of 12 were males and 7 out of these 10 males had BK VL more than 10 3 copies/ml, 9 out of 12 had renal transplantation within less than 12 months and 6 of these 9 patients had BK VL more than 10 3 copies/ml, According to our standard curve, 58.3% (7/12) had BK viral load more than 1X10 3 copies/ml, with a mean of 1.99X10 8 copies/ml. In addition, 41.7 % (5/12) had biopsy proven BKVN, i.e. 5.05% (5/99 RTR) had BKVN, 4 of these 5 cases (80%) had BK viral load of more than 1X10 4 copies/ml, and three of these 5 cases (60%) have lost their graft. Regarding donor/ recipient CMV serostate, there was no significant difference in donor/ recipient CMV serostate among the 12 BK viremic patients. However, the study revealed a significant positive correlation between serum creatinine value and BK VL; (r=+0.576, p=0.05), figure (2). But, only 3 out of the 19 RTR patients who had rejection, had BK viremia; which shows no significant correlation (p=0.581), and only one of the 5 patients who were receiving ATG (anti-thymocyteglobuline) had BK viremia. There was a significant difference in BKV viremia rates between samples from the biopsy proven BKVN and remaining BK positive cases (p=0.03). Furthermore, the study showed a highly significant association between BKV positivity and ureteric stenosis cases (p=0.007). 135
6 Figure (2): Correlation between serum creatinine value and BK viral load (r=+0.576, p=0.05) Despite the none significant correlation between the type of immunosuppressive regimen used and BK viremia (p=0.42), this study showed that 50% (4 out of 8) BKV positive patients who were receiving TAC regimen had BK VL more than 1x10 4 copies/ml, and all of the 5 patients who had biopsy proven BKV nephropathy (BKVN) were on TAC regimen. Finally, the results of this study demonstrated a highly significant association between BKV positivity and decoy cells positivity in Pap-stained urine cytology smears (p=0.001). Moreover, all cases who had uncommon decoy cells in urine cytology smears were positive for BKV (p=0.001), table (1) A and B respectively. However, there was no significant correlation between the number of decoy cells per urine cytology smear and BK VL (r=0.111, p=730). Table (1): The prevalence of: A; Decoy cells shedding, and B; Uncommon decoy cells shedding in cases positive for BK viremia among the 99 RTR. A BK viremia Total p Negative Positive value Decoy cells Negative Count % 100.0% 0.0% 100.0% Positive Count % 55.6% 44.4% 100.0% Total Count % 87.9% 12.1% 100.0% B BK viremia Total p value Uncommon DC Negative Positive Negative Count % 95.6% 4.4% 100.0% Positive Count % 0.0% 100.0% 100.0% Total Count % 87.9% 12.1% 100.0% 136
7 Discussion By using more potent immunosuppressive regimens to decrease acute rejection rates in RTRs, viral infections had emerged as an important cause of allograft loss. BKV is one of the common post-transplant viral infections (2,6), in this study, the prevalence of BK viremia was 12.12%, which lies within the range of overall incidence of BK viremia that range from 11% to 29% (19,20). Following the detection of viruria, some patients develop viremia. BK viremia is believed to result from a more extensive infection leading to severe tubular injury with rupture of tubular basement membranes and entry of the virus into the blood stream via peritubular capillaries. Ultimately, sustained viremia is associated with BKVN in 1% to 10% of RTRs (11,21,22), in which also the prevalence of BKVN (5.05%) in our study lies within this range. Studies found that BK viremia and BKVN are most common in the first year after transplantation, when immunosuppression is most intense (23,24), which are in line with our results which showed that (75%) 9 out of 12 had renal transplantation within less than 12 months, and 66.7%, 6 of these 9 patients had BK VL more than 10 3 copies/ml. However, some workers found that early, during the first month following transplantation, BKVN can occur only exceptionally (7). This explains our reason behind collecting RTR patients with a post-transplant period ranging between 2-30 months and not less than 2 months. In addition, these studies showed that BKV reactivation is usually associated with ureteric stenosis and bacterial urinary tract infections (23,24), which also support the results of this study in which 2 out of the 12 viremic patients had bacterial urinary tract infection, and another 2 out of the 12 viremic patients had ureteric stenosis (among the only 4 out of 99 RTR who had ureteric stenosis) (p=0.007). In the majority of patients, BK viremia and progression of BKVN are asymptomatic except only for steadily increasing serum creatinine concentrations (25-27). A presentation that is very obvious in our viremic patients is that there was a significant positive correlation between serum creatinine value and BK VL; (r=+0.576, p=0.05), figure (2). And this increasing serum creatinine often makes most of the physicians to misdiagnose BKVN as an acute rejection or drug toxicity (28). Results of our study showed a significant difference between the median BK VL in plasma from the biopsy proven BKVN and the remaining BK viremic patients (1.82x10 5 versus 1.82x10 2 ) copies/ml (p=0.03), in which 4 out of 5 BKVN cases had BK VL levels more than 1x10 4 copies/ml. The American Society of Transplantation (AST) defines a BK 137
8 VL of 4 log10/ml (1x10 4 copies) as presumptive BKVN, and recommends reduction in immunosuppression (25), which is also supported by other studies (11), which is in agreement with our results. However, a recent study showed that these current AST guidelines have underestimated the diagnosis of BKVN, and a cut off BK VL of (1x10 4 copies) might not necessarily indicate a presumptive BKVN, and even lower values of plasma viral load could sometimes associated with BKVN (29). This finding explains why one of the 5 BKVN cases in our study had BK VL less than (1x10 4 copies). The suggested risk factors for BKVN and BK viremia, included mainly the recipient factors (older age, male gender, low or absent BKV-specific T-cell activity) (25,30), in the present study, although it was not significant by relative risk study, 7 patients out of the 12 BK positive cases were above 40 years old and (85.7%) i.e. 6 of these 7 patients had BK VL more than 10 3 copies/ml. Also (83.3%) 10 out of 12 were males and (70%) 7 out of these 10 males had BK VL more than 10 3 copies/ml. Although RR study showed none significant correlation between the type of immunosuppressive regimen (whether TAC or CSA) and BK viremia, 66.7% (8/12) patients were on TAC regimen, 50% (4/8) had BK VL more than 1x10 4 copies/ml, and all of the 5 patients who had biopsy proven BKV nephropathy (BKVN) were on TAC regimen, a finding that is in agreement with the study of Hirsch et al (3), which showed that high-titer BK VL (>4 log) 10 4 copies/ml, and the overall median BK VLs were higher in the TAC group. In 2009, Egli et al. (31) demonstrated that TAC therapy inhibits BKV-specific T cell immune response, and the reduction of immunosuppressive therapies has led to an increase in the BKV-specific cellular immune response. However, both TAC and CSA were shown to cause dose-dependent inhibition of IFN-γ expression by BKV-specific T cell response (4,32). BKV shedding into the urine occurs in 10-30% of renal transplant recipients, and prospective monitoring of RTRs may identify patients with active infection before deterioration of the renal function. BKV cytopathic effect is a well-recognized entity in urine cytology specimens. Virus-infected cells termed (decoy cells) can be found in urine samples, and may mimic the nuclear changes that occur in urothelial cancer (33). Results of this study showed that the rate of occurrence of DCs as a marker of viral replication was 27.27%, and all of the 12 BK viremic patients were decoy positive that is similar to the majority of studies on the detection of DCs in RTRs (34-37), which make it a cost-effective and powerful screening method. On the other hand, this study showed no 138
9 significant correlation between BKV load and the number of DCs which is supported by the study of Nickeleitet al., which showed that higher numbers of DCs do not indicate a higher risk level (37). Based on the morphologic features alone, one cannot always distinguish between BKV excretion and other viral infections. DCs might result from infection with BKV, JCV, and less commonly, adenoviruses (34,38). However JCV and adenoviruses rarely cause nephropathy in RTRs (39,40). BKV PCR does not face the obstacles that limit urine cytology and can ultimately prove superior in screening for BKVN. A study compared BKV PCR with urine cytology, by evaluating 114 patients for evidence of BK viremia and DCs, along with concurrent renal biopsy in order to correlate with an actual BKVN. Results indicated that, identification of DCs as a marker of BKV viruria had a sensitivity of 25%, and a specificity of 84%. While the sensitivity and specificity of BKV PCR on plasma for BK viremia was 100% and 91% respectively. Also, BKV PCR on plasma and urine had superior positive and negative predictive values for biopsy-proven, concurrent BKVN (10). Acknowledgment This research is funded by the Research and Development Department RDD of the Iraqi Ministry of Higher Education and Scientific Research, project of supporting post-graduate students ( Conflict of Interest: Authors declare no conflict of interest. List of abbreviations: BKV= BK virus BKVN= BK virusnephropathy RTR= renal transplant recipient LD= living donor CKD= chronic kidney disease RT-PCR= real time PCR DC= decoy cell References 1. Tremolada S, Akan S, Otte J et al. Rare subtypes of BK virus are viable and frequently detected in renal transplant recipients with BK virus-associated nephropathy. Virology 2010; 404: Koukoulaki M, Grispou E, Pistolas D, et al. Prospective monitoring of BK virus replication in renal transplant recipients. Transplant Infect Dis 2009;11: Hirsch HH, Vincenti F, Friman S et al.polyomavirus BK replication in denovo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant 2013; 13: Bohl DL and Brennan DC. BK Virus Nephropathy and Kidney Transplantation. Clin J Am SocNephrol 2007; 2: S36 S
10 5. Gardner SD, MacKenzie EF, Smith C, Porter AA. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J ClinPathol 1984;37: Sawinski D and Goral S. BK virus infection: an update on diagnosis and treatment. Nephrol Dial Transplant 2014; 10: Mihatsch MJ. Polyomavirus nephropathy: a brief review with special emphasis on clinico-patholgical aspects. Sec. Biol. Med. Sci., MASA, XXXIII, 2012; 2: Drachenberg CB, Papadimitriou JC, Hirsch HH. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004; 4: Rogers NM, Russ GR, Cooper J, Coates PT. Immunophenotyping of interstitial infiltrate does not distinguish between BK virus nephropathy and acute cellular rejection. Nephrology (Carlton) 2009; 14 (1): Viscount HB, Eid AJ, Espy MJ, et al.polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus associated nephropathy. Transplantation 2007;84: Hirsch HH, Brennan DC, Drachenberg CB, et al.polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79(10): Maia TMC, Silva SFR, Silva SL, et al.polyomavirus-infected Decoy Cells in Cytocentrifuged Urine Cytology Specimens from Renal Transplant Recipients. ActaCytologica 2011;55: Chakera A, Dyar OJ, Hughes E, et al. Detection of Polyomavirus BK Reactivation After Renal Transplantation Using an Intensive Decoy Cell Surveillance Program Is Cost-Effective. Transplant 2011;XX: Kapila K, Nampoory MR, Johny KV, et al. Role of urinary cytology in detecting human polyoma BK virus in kidney transplant recipients. A preliminary report. Med PrincPract 2007;16: Kipp BR, Sebo TJ, Griffin MT, et al: Analysis of Polyomavirus- Infected Renal Transplant Recipient's Urine Specimens. Am J ClinPathol. 2005;124: Smith JM and Davis CL: Screening for BK virus in pediatric renal transplant recipients. PediatrTranspl. 2010:14: Gai M, Lanfranco G, Segoloni GP. Decoy cells in urine. Transplant Proc 2005; 37: Singh HK, Shen YJ, Detwiler R, et al.polyomavirus inclusion-bearing decoy cell phenotypes: role in the management of patients with polyomavirus-bk nephropathy (BKN). J Am SocNephrol (abstracts issue) 2006; 17:761A Bressollette-Bodin C, Coste-Burel M, Hourmant M, et al. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant 2005;5: Agha I, Brennan DC: BK virus and immunosuppressive agents. AdvExp Med Biol 2006; 577: Hirsch HH. BK Virus: Opportunity Makes a Pathogen. ClinInfec Dis 2005; 41: Hirsch HH, and Steiger J. Polyomavirus BK. Lancet Infect Dis 2003; 3: Howell DN, Smith SR, Butterly DW, et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999;68: Binet I, Nickeleit V, Hirsch HH et al: Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplant 1999; 67: Hirsch HH, and Randhawa P: BK Virus in Solid Organ Transplant Recipients. Am J Transpl 2009; 9(Suppl 4): S136 S Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: Charles J. Bechert, Vicki J et al: Monitoring of BK Viral Load in Renal Allograft Recipients by Real-Time PCR Assays. Am J ClinPathol 2010;133: Mischitelli M, Bellizzi A, Anzivino E, et al: Complications post renal transplantation: literature focus on BK virus nephropathy and diagnostic tools actually available. Viro J 2008, 5: Hassan S, Mittal C, Amer S, et al. Currently recommended BK virus (BKV) plasma viral load cutoff of 4 log10/ml underestimates the diagnosis of BKV-associated nephropathy: a single transplant center experience. Transplant Infect Dis 2014: 16: Barraclough KA, Isbel NM, Staatz CE, and Johnson DW. Clinical Study: BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression. J of Transpl.2011;2011: Egli A, Infanti L, Dumoulin A: Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors. J Infect Dis 2009; 199: Abend JR, Low JA, Imperiale MJ: Inhibitory Effect of Gamma Interferon on BK Virus Gene Expression and Replication. J. Virol. 2007, 81(1): DeMay RM. Exfoliative Cytology. In Chicago, IL. The Art and Science of Cytopathology; Vol. 1. ASCP Press; 1996:
11 Boldorini R, Brustia M, Veggiani C, et al. Periodic assessment of urine and serum by cytology and molecular biology as a diagnostic tool for BK virus nephropathy in renal transplant patients. ActaCytol 2005; 49: Singh HK, Bubendorf L, Mihatsch MJ, et al.: Urine cytology findings of polyomavirus infections. In: Ahsan N, ed. Polyomaviruses and Human Diseases, 1st edn. New York/Georgetown: Springer Science /Business Media, Landes Bioscience/Eurekah.com, 2006: Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002;347: Nickeleit V, Steiger J, Mihatsch MJ. BK virus infection after kidney transplantation. Graft 2002; 5: S Itoh S, Irie K, Nakamura Y. Cytologic and genetic study of polyomavirus-infected or polyomavirus-activated cells in human urine. Arch Pathol Lab Med 1998;122: Kazory A, Ducloux D, Chalopin JM, et al. The first case of JC virus allograft nephropathy [letter]. Transplantation 2003;76: Wen MC, Wang CL, Wang M, et al. Association of JC virus with tubulointerstitial nephritis in a renal allograft recipient. J Med Virol 2004;72:
ClinicalValidation Study of Quantitative Real-Time PCR Assay for Detection and Monitoring of BK Virus Nephropathy
Available online at www.annclinlabsci.org ClinicalValidation Study of Quantitative Real-Time PCR Assay for Detection and Monitoring of BK Virus Nephropathy 455 Satoru Kudose 1 and Jianli Dong 2 Departments
More informationJournal of Global Pharma Technology
Journal of Global Pharma Technology Available Online at www.jgpt.co.in ISSN: 0975-8542 RESEARCH ARTICLE The Possible Role of JC Polyomavirus after Kidney Transplantation Asmaa B Al-Obaidi 1, Haidar A Shamran
More informationDECOY CELLS IN KIDNEY TRANSPLANT RECIPIENTS
DECOY CELLS IN KIDNEY TRANSPLANT RECIPIENTS GIOVANNI BATTISTA FOGAZZI CLINICAL AND RESEARCH LABORATORY ON URINARY SEDIMENT U.O. DI NEFROLOGIA E DIALISI FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationClinical Grand Rounds. May 2016
Clinical Grand Rounds May 2016 The Case 51M African American w/ HTN, ESRD (on HD for 13 years) who underwent a DDRTx in June 2015. Complications: BK viremia with AKI in Jan 2016---MMF held and tacro dose
More informationThe New England Journal of Medicine PROSPECTIVE STUDY OF POLYOMAVIRUS TYPE BK REPLICATION AND NEPHROPATHY IN RENAL-TRANSPLANT RECIPIENTS
PROSPECTIVE STUDY OF POLYOMAVUS TYPE BK REPLICATION AND NEPHROPATHY IN RENAL-TRANSPLANT RECIPIENTS HANS H. HSCH, M.D., WENDY KNOWLES, PH.D., MICHAEL DICKENMANN, M.D., JAKOB PASSWEG, M.D., THOMAS KLIMKAIT,
More informationRisk factors in the progression of BK virus-associated nephropathy in renal transplant recipients
ORIGINAL ARTICLE Korean J Intern Med 15;3:865-872 http://dx.doi.org/1.394/kjim.15.3.6.865 Risk factors in the progression of BK virus-associated nephropathy in renal transplant recipients Hae Min Lee 1,*,
More informationIntravenous immunoglobulin in BK virus nephropathy
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Intravenous immunoglobulin in BK virus nephropathy Elizabeth I. Anyaegbu Driscoll Children's Hospital Stanley
More informationPREVENTION AND TREATMENT OF BKV NEPHROPATHY Petra Reinke, Berlin, Germany. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy
PREVENTION AND TREATMENT OF BKV NEPHROPATHY Petra Reinke, Berlin, Germany Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Petra Reinke Department of Nephrology University Hospital
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationLack of Significant Co-Activation of BKV and CMV in Renal Transplant Patients: An Institutional Experience
Volume 1, Issue 1, pp: 1-6 Research Article Introduction Open Access Lack of Significant Co-Activation of BKV and CMV in Renal Transplant Patients: An Institutional Experience Minh-Thu Nguyen, BS 1, Phylicia
More informationHistological Patterns of Polyomavirus Nephropathy: Correlation with Graft Outcome and Viral Load
American Journal of Transplantation 2004; 4: 2082 2092 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2004 doi: 10.1111/j.1600-6143.2004.00603.x Histological Patterns of Polyomavirus Nephropathy:
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationDecoy Cell Viruria in Kidney Transplant Patients. Does it correlate with Renal Function?
Decoy Cell Viruria in Kidney Transplant Patients. Does it correlate with Renal Function? Akram Abedi (1) Mojgan Mortazavi (2) Omid Mirmosayyeb (3,4) Shahram Taheri (2) Nooshin Afsharmoghadam (1) Majid
More informationClinical significance of quantitative and qualitative detection of BK and JC virus in blood and urine of renal transplantation recipients
Open Access Original Article Clinical significance of quantitative and qualitative detection of BK and JC virus in blood and urine of renal transplantation recipients Liangwei Qiao 1, Qingshan Qu 2, Xin
More informationBK Virus Encoded MicroRNAs Are Present in Blood of Renal Transplant Recipients With BK Viral Nephropathy
American Journal of Transplantation 2014; 14: 1183 1190 Wiley Periodicals Inc. Brief Communication C Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationOTKA azonosító: Típus: K Vezető kutató: Gergely Lajos
Human herpesvirus 6 (HHV-6), mostly variant B reactivation in renal transplant patients has been published previously, but the pathogenetic role of HHV-6 variant A has not been clarified. During the project
More informationQuantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN
NEW MICROBIOLOGICA, 34, 165-171, 2011 Quantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN Caterina Patrizia Pollara 1, Silvia Corbellini
More informationPrevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients
TRANSPLANTATION Prevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients Mohsen Nafar, 1 Azamolsadat Roshan, 2 Fatemeh Pour-Reza-Gholi, 1 Fariba Samadian, 1 Pedram
More informationTrends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant and relationship to BK virus infection
2565 Nephrol Dial Transplant (2012) 27: 2565 2570 doi: 10.1093/ndt/gfr675 Advance Access publication 13 December 2011 Trends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant
More informationTranspla. antation. Associate Professor of Medical Virology Virology Research Center Shahid Beheshti University of Medical Sciences
Viral Mo olecular Diagno osis in Transpla antation Seyed Alireza Nadji, Ph.D. Associate Professor of Medical Virology Virology Research Center Shahid Beheshti University of Medical Sciences Which techniques
More informationOptimal use of plasma and urine BK viral loads for screening and predicting BK nephropathy
Boan et al. BMC Infectious Diseases (2016) 16:342 DOI 10.1186/s12879-016-1652-6 RESEARCH ARTICLE Open Access Optimal use of plasma and urine BK viral loads for screening and predicting BK nephropathy Peter
More informationTESTING FOR POLYOMAVIRUS BK DNA TO IDENTIFY RENAL-ALLOGRAFT RECIPIENTS WITH VIRAL NEPHROPATHY
TESTING FOR POLYOMAVIRUS TYPE BK DNA IN PLASMA TO IDENTIFY RENAL-ALLOGRAFT RECIPIENTS WITH VIRAL NEPHROPATHY VOLKER NICKELEIT, M.D., THOMAS KLIMKAIT, PH.D., ISABELLE F. BINET, M.D., PETER DALQUEN, M.D.,
More informationBK virus nephritis after renal transplantation
http://www.kidney-international.org & 2006 International Society of Nephrology review BK virus nephritis after renal transplantation S Hariharan 1 1 Division of Nephrology, Medical College of Wisconsin,
More informationSince the 1990s, renal transplantation has become the treatment
Polyomavirus in Renal Transplantation: A Hot Problem Catherine Bonvoisin, Laurent Weekers, Patricia Xhignesse, Stéphanie Grosch, Miroslav Milicevic, and Jean-Marie Krzesinski Polyomavirus BK has emerged
More informationBK virus, kidney transplant, polycystic kidney disease. 1-3 Following mild or asymptomatic primary infection, typically early
Received: 22 June 2018 Revised: 17 July 2018 Accepted: 6 August 2018 DOI: 10.1111/tid.12974 ORIGINAL ARTICLE Kidney transplant recipients with polycystic kidney disease have a lower risk of post- transplant
More informationCases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center
Cases: CMV, HCV, BKV and Kidney Transplantation Simin Goral, MD University of Pennsylvania Medical Center Disclosures Grant support: Otsuka Pharmaceuticals, Astellas Pharma, Angion, AstraZeneca, and Kadmon
More informationRecognition and Treatment of Chronic Allograft Dysfunction
Recognition and Treatment of Chronic Allograft Dysfunction Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs
More informationImpact of Subclinical Rejection on Transplantation
Trends in Transplantation 2007;1:56-60 Impact of Subclinical Rejection on Transplantation David N. Rush for the Winnipeg Transplant Group Transplant Manitoba Adult Kidney Program, University of Manitoba,
More informationAdjuvant Role of p53 Immunostaining in Detecting BK Viral Infection in Renal Allograft Biopsies
Available online at www.annclinlabsci.org 324 Annals of Clinical & Laboratory Science, vol. 40, no. 4, 2010 Adjuvant Role of p53 Immunostaining in Detecting BK Viral Infection in Renal Allograft Biopsies
More informationDevelopment of a BK Virus Real-Time Quantitative Assay Using the biomérieux Analyte-Specific Reagents in Plasma Specimens
Development of a BK Virus Real-Time Quantitative Assay Using the biomérieux Analyte-Specific Reagents in Plasma Specimens Hanna Rennert, PhD, 1,2 Helen Fernandes, PhD, 1,2 Zahid Gilani, 2 and John Sipley,
More informationBK Viral Infection and Malignancy in Renal Transplantation ~A Case History~
BK Viral Infection and Malignancy in Renal Transplantation ~A Case History~ Mariko Toyoda, MD Department of Nephrology, Japanese Red Cross Kumamoto Hospital Statement of Disclosure The author does not
More informationBK virus nephropathy (BKVN) has emerged as an important
BK Virus Nephropathy in Pediatric Renal Transplant Recipients: An Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry Jodi M. Smith,* Vikas R. Dharnidharka,
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More information1266 TRANSPLANTATION. Vol. 75, No. 8
1266 TRANSPLANTATION codynamic studies of one or two doses of daclizumab in renal transplant patients. Am J Transplant 2001; 1: 385 (A 991). 12. Niemeyer G, Koch M, Light S, et al. Long-term safety, tolerability
More informationRENAL EVENING SPECIALTY CONFERENCE
RENAL EVENING SPECIALTY CONFERENCE Harsharan K. Singh, MD The University of North Carolina at Chapel Hill Disclosure of Relevant Financial Relationships No conflicts of interest to disclose. CLINICAL HISTORY
More informationDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA 2
Transplantation Volume 2012, Article ID 761283, 7 pages doi:10.1155/2012/761283 Clinical Study Progression from Sustained BK Viruria to Sustained BK Viremia with Immunosuppression Reduction Is Not Associated
More informationGouvêa et al. Journal of Medical Case Reports (2017) 11:146 DOI /s
Gouvêa et al. Journal of Medical Case Reports (2017) 11:146 DOI 10.1186/s13256-017-1300-9 CASE REPORT Open Access BK polyomavirus nephropathy in two kidney transplant patients with distinct diagnostic
More informationABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies
Nephrol Dial Transplant (2009) 24: 298 303 doi: 10.1093/ndt/gfn478 Advance Access publication 26 August 2008 Original Article ABO blood group-incompatible living donor kidney transplantation: a prospective,
More informationCytomegalovirus (CMV) Viral Load in Bronchoalveolar Lavage Fluid (BALF) and Plasma to Diagnose Lung Transplant Associated CMV Pneumonia
Cytomegalovirus (CMV) Viral Load in Bronchoalveolar Lavage Fluid (BALF) and Plasma to Diagnose Lung Transplant Associated CMV Pneumonia I.P. Lodding 1,2, H.H. Schultz 3, J.U. Jensen 1,5, C. Andersen 4,
More informationAs immunosuppression for kidney transplantation
NARRATIVE REVIEW Polyomavirus Nephropathy: A Current Perspective and Clinical Considerations Alexander C. Wiseman, MD During the last decade, the human polyomaviruses (BK virus and, much less commonly,
More informationTransient versus Persistent BK Viremia and Long-Term Outcomes after Kidney and Kidney Pancreas Transplantation
Article Transient versus Persistent and Long-Term Outcomes after Kidney and Kidney Pancreas Transplantation Nissreen Elfadawy,* Stuart M. Flechner,* Jesse D. Schold, Titte R. Srinivas, Emilio Poggio,*
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationUse of Viral Load Testing in Managing CMV Infections in SOTR
Use of Viral Load Testing in Managing CMV Infections in SOTR Angela M. Caliendo, MD, PhD, FIDSA Professor and Vice Chair, Medicine Alpert Medical School of Brown University Providence, RI Disclosures Scientific
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationRecurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab
TRANSPLANTATION Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab Khadijeh Makhdoomi, 1,2 Saeed Abkhiz, 1,2 Farahnaz Noroozinia, 1,3
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationA clear path forward AVAILABLE NOW THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
AVAILABLE NOW A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test that assesses organ
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationEuropean perspective on human polyomavirus infection, replication and disease in solid organ transplantation
REVIEW 10.1111/1469-0691.12538 European perspective on human polyomavirus infection, replication and disease in solid organ transplantation H. H. Hirsch 1,2, N. Babel 3, P. Comoli 4, V. Friman 5, F. Ginevri
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationWorld Journal of Transplantation. BK nephropathy in the native kidneys of patients with organ transplants: Clinical spectrum of BK infection
W J T World Journal of Transplantation Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.472 World J Transplant 2016 September
More informationSV40 Detection and Transmission: Does SV40 Circulate in Human Communities?
SV40 Detection and Transmission: Does SV40 Circulate in Human Communities? Keerti Shah, Dana Rollison and Raphael Viscidi Johns Hopkins Medical Institutions Baltimore, MD Background A large number of cancer
More informationTransplantation simplified. Dr Jasna Macanovic Consultant Nephrologist Wessex Renal and Transplant Services Portsmouth, UK
Transplantation simplified Dr Jasna Macanovic Consultant Nephrologist Wessex Renal and Transplant Services Portsmouth, UK HISTORY The first successful kidney transplant was performed in 1954 between identical
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationInt J Clin Exp Med 2015;8(9): /ISSN: /IJCEM
Int J Clin Exp Med 2015;8(9):16340-16345 www.ijcem.com /ISSN:1940-5901/IJCEM0011301 Original Article Comparison of anti-reflux mechanism between Double-J-Stent and standart Double-J-Stent use for risk
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationStudy of systemic fungal infections in renal transplant recipients
Original Research Article Study of systemic fungal infections in renal transplant recipients N.D. Srinivasaprasad 1*, G. Chandramohan 1, M. Edwin Fernando 2 1 DM (Nephrology), Assistant Professor, 2 DM
More informationHow do the KDIGO Clinical Practice Guidelines on the Care of Kidney Transplant Recipients apply to the UK?
How do the KDIGO Clinical Practice Guidelines on the Care of Kidney Transplant Recipients apply to the UK? Dr Richard Baker & Professor Alan Jardine, co-authors, forthcoming Renal Association module on
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationPersistent BK Viremia Does Not Increase Intermediate- Term Graft Loss but Is Associated with De Novo Donor-Specific Antibodies
CLINICAL RESEARCH www.jasn.org Persistent BK Viremia Does Not Increase Intermediate- Term Graft Loss but Is Associated with De Novo Donor-Specific Antibodies Deirdre Sawinski,* Kimberly A. Forde, Jennifer
More informationPatient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant
Patient Education Glossary of Terms For a kidney/pancreas transplant Glossary of Terms Page 18-2 Antibody A protein substance made by the body s immune system in response to a foreign substance. Antibodies
More informationSimultaneous pancreas/kidney transplant recipients present with late-onset BK polyomavirus-associated nephropathy
16. Paoletti E, Marsano L, Bellino D et al. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients; a 1 year, randomized, controlled trial. Transplantation 2012; 93:
More informationImproving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M)
OFF-THE-SHELF T CELL THERAPY FOR CANCER PATIENTS FOLLOWING STEM CELL TRANSPLANT Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M) Ann M.
More informationSevere Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia
Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia Liat Shragian Alon, MD Rabin Medical Center, ISRAEL #EBMT15 www.ebmt.org Patient: 25-year-old male No prior medical history
More informationReview of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology
Review of Rituximab and renal transplantation Dr.E Nemati Professor of Nephrology Introductio n Rituximab is a chimeric anti-cd20 monoclonal antibody. The CD20 antigen is a transmembrane nonglycosylated
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationClinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients
Original Research Article Clinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients Surendran Sujit 1*, N. Gopalakrishnan 2 1 Assistant Professor, 2 Professor and Head Department
More informationA clear path forward COMING SOON THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
COMING SOON A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test which assesses organ
More informationBK Virus: Opportunity Makes a Pathogen
IMMUNOCOMPROMISED HOSTS David R. Snydman, Section Editor INVITED ARTICLE BK Virus: Opportunity Makes a Pathogen Hans H. Hirsch Transplantation Virology, Department of Clinical Biological Sciences, University
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationPresence of Urinary Haufen Accurately Predicts Polyomavirus Nephropathy
JASN Express. Published on January 21, 2009 as doi: 10.1681/ASN.2008010117 www.jasn.org Presence of Urinary Haufen Accurately Predicts Polyomavirus Nephropathy Harsharan K. Singh,* Kenneth A. Andreoni,
More informationViral Infections after Transplantation
Viral Infections after Transplantation Burkhard Tönshoff, MD, PhD University Children s Hospital Heidelberg Pediatric Transplantation Teaching Course, Moscow 2016 OVERVIEW Timeline of post-transplant infections
More informationRenal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic
Renal Pathology- Transplantation Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz Kidney has a limited number of tissue reactions by which the kidney
More informationPrimary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis
American Journal of Transplantation 2010; 10: 2026 2032 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant
More informationImmunomodulator y effects of CMV disease
Immunomodulator y effects of CMV disease Oriol Manuel MD Service of Infectious Diseases and Transplantation Center University Hospital of Lausanne Switzerland Outline The transplant troll The indirect
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationPulmonary AMR Therapeutic Options & Strategies: The Old and the New. Ramsey Hachem, MD March 28, 2017
Pulmonary AMR Therapeutic Options & Strategies: The Old and the New Ramsey Hachem, MD March 28, 2017 Disclosures Ramsey Hachem I have no financial relations with any relevant commercial interests I will
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationPediatric Kidney Transplantation
Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated
More informationProgressive Multifocal Leukoencephalopathy (PML)
Progressive Multifocal Leukoencephalopathy (PML) By Jamie Meier Introduction: Progressive multifocal leukoencephalopathy (PML) occurs when change in an individual s immune status triggers reactivation
More informationLa Terapia Cellulare nella PML
Update sulle Malattie Infiammatorie e Infettive del SNC Pavia, 25 maggio 218 La Terapia Cellulare nella PML Sabrina Basso Oncoematologia Pediatrica Fondazione IRCCS Policlinico S. Matteo, Pavia Polyomavirus
More informationHIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER
HIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER Gaston Zilleruelo M.D. Professor of Pediatrics Director of Pediatric Nephrology University of Miami/Holtz Children s Hospital Worldwide 33.2 million
More informationTID-17-C-005.R1, Received: 21 January 2017, Revised: 13 June 2017, Accepted: 29 June 2017
DR ROMÁN HERNÁNDEZ-GALLEGO (Orcid ID : 0000-0002-5670-941X) Article type : Case Report TID-17-C-005.R1, Received: 21 January 2017, Revised: 13 June 2017, Accepted: 29 June 2017 CASE REPORT Anemia as very
More informationPathology and Management of Chronic Allograft Dysfunction. Simin Goral, MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
Pathology and Management of Chronic Allograft Dysfunction Simin Goral, MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Mission Impossible? PLAN To review the description of chronic
More informationAntimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association
Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk
More informationKidney Summary. Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA
Kidney Summary Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Key Issues to Address re: the Classification 1. Incorporation of i-ifta + tubulitis into the TCMR classification - Defining
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. Optimizing use of organs from Increased Risk Donors
2017 CST-Astellas Canadian Transplant Fellows Symposium Optimizing use of organs from Increased Risk Donors Atual Humar, MD Atul Humar is a Professor in the Department of Medicine, University of Toronto.
More informationThe application of cytology in urological diseases
Voided urine cytology The application of cytology in urological diseases Dr Ashish Chandra FRCPath DipRCPath (Cytol) Guy s & St Thomas NHSfT London Detection of high grade urothelial carcinoma Monitoring
More informationACTIVITY OF BRINCIDOFOVIR (BCV) AGAINST MURINE POLYOMAVIRUS (MUPYV) IN A MOUSE INFECTION MODEL
ACTIVITY OF BRINCIDOFOVIR (BCV) AGAINST MURINE POLYOMAVIRUS (MUPYV) IN A MOUSE INFECTION MODEL Kidney Week 2018 Poster # SA-PO642 BRINCIDOFOVIR(BCV) DEMONSTRATES ANTIVIRAL ACTIVITY AGAINST MURINE POLYOMAVIRUS
More informationBidirectional Interaction between Cytomegalovirus and Hepatitis C Virus after Liver Transplantation: A Critical Review of the Clinical Evidence
Trends in Transplantation Transplant. 2008;2:148-56 2008;3 Bidirectional Interaction between Cytomegalovirus and Hepatitis C Virus after Liver Transplantation: A Critical Review of the Clinical Evidence
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationTopic BKV Polyoma Virus
Topic 13.1. BKV Polyoma Virus Author: Helen Pilmore and Paul Manley GUIDELINES a. We suggest screening high risk kidney transplant recipients for BK polyoma virus (BKV) with quantitative plasma NAT. The
More informationJames E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant
James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest
More information